THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY

被引:52
作者
FARIASEISNER, R [1 ]
TENG, F [1 ]
OLIVEIRA, M [1 ]
LEUCHTER, R [1 ]
KARLAN, B [1 ]
LAGASSE, LD [1 ]
BEREK, JS [1 ]
机构
[1] CEDARS SINAI MED CTR,LOS ANGELES,CA 90048
关键词
D O I
10.1006/gyno.1994.1257
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to determine the influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual epithelial ovarian cancer after primary optimal cytoreductive surgery. Between 1978 and 1990, 112 patients with stage III epithelial ovarian cancer underwent primary cyto-reductive surgery and had minimal residual disease, i.e., <5 mm maximum diameter of residual tumor nodules. Seventy-eight patients (70%) had operative reports that contained sufficient detail to be included in this study. We retrospectively reviewed histopathological reports to determine tumor grade, operative and clinical notes to determine one predominant distribution pattern of residual metastases (pelvic/omental, diaphragmatic, or intestinal/mesenteric), and the approximate extent of residual disease (no gross disease, scattered nodules, or extensive carcinomatosis). Standard actuarial survival analysis was performed, and the long-rank chi2 was used. At the mean follow-up time of 24.4 months, survival was 65% for grade 2 or 3 disease versus 93% for grade 1 (log-rank P < 0.01). Survival was 66% for residual disease in the intestines/mesentery versus respectively (log-rank P < 0.001). In conclusion, in women who have minimal residual ovarian cancer after primary cytoreductive surgery, tumor grade and the distribution and extent of carcinomatosis can independently affect survival. The shortest survival correlated with high-grade tumor and extensive carcinomatosis predominantly involving the intestines and mesentery. (C) 1994 Academic Press, Inc.
引用
收藏
页码:108 / 110
页数:3
相关论文
共 20 条
[1]  
BEREK JS, 1990, PRACTICAL GYNECOLOGI, P327
[2]   CANCER STATISTICS, 1994 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T ;
MONTGOMERY, S .
CA-A CANCER JOURNAL FOR CLINICIANS, 1994, 44 (01) :7-26
[3]   CISPLATIN, METHOTREXATE, AND 5-FLUOROURACIL COMBINATION CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER [J].
CONTE, PF ;
SERTOLI, MR ;
BRUZZONE, M ;
RUBAGOTTI, A ;
ROSSO, R ;
BENTIVOGLIO, G ;
CONIO, A ;
PESCETTO, G .
GYNECOLOGIC ONCOLOGY, 1985, 20 (03) :290-297
[4]   STAGE-III EPITHELIAL OVARIAN-CANCER - THE ROLE OF MAXIMAL SURGICAL REDUCTION [J].
DELGADO, G ;
ORAM, DH ;
PETRILLI, ES .
GYNECOLOGIC ONCOLOGY, 1984, 18 (03) :293-298
[5]  
GOLDIE JH, 1989, PRINCIPLES PRACTICE, V3, P1
[6]  
HACKER NF, 1983, OBSTET GYNECOL, V61, P413
[7]   ADVANCED OVARIAN-CANCER - LONG-TERM RESULTS OF TREATMENT WITH INTENSIVE CISPLATIN-BASED CHEMOTHERAPY OF BRIEF DURATION [J].
HAINSWORTH, JD ;
GROSH, WW ;
BURNETT, LS ;
JONES, HW ;
WOLFF, SN ;
GRECO, FA .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (02) :165-170
[8]   THE TREATMENT OF ADVANCED OVARIAN-CARCINOMA .1. CLINICAL-VARIABLES ASSOCIATED WITH PROGNOSIS [J].
HEINTZ, APM ;
VANOOSTEROM, AT ;
BAPTIST, J ;
TRIMBOS, MC ;
SCHABERG, A ;
VANDERVELDE, EA ;
NOOY, M .
GYNECOLOGIC ONCOLOGY, 1988, 30 (03) :347-358
[9]  
HOSKINS WJ, 1991, SEMIN ONCOL, V18, P213
[10]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481